Research demonstrates effective biotransformation of biliverdin to bilirubin in yeast, suggesting a new production method.
Bilirubin is a key component in the preparation of two traditional Chinese medicines: Calculus bovis sativus and Calculus bovis artifactus. Currently, industrial-scale production of bilirubin is limited to extraction from pig bile in a very low yield and its market price is very high, so it is important to develop an alternative method for producing bilirubin. This study developed a potential process for bilirubin production through biotransformation of biliverdin. The codon-optimized gene for biliverdin reductase (BVR) from Synechocystis PCC6803 was recombinantly expressed in Komagataella phaffii GS115, resulting in the genetically modified strain GS115-bvdR, which successfully expressed BVR with intracellular activity. Whole cells of GS115-bvdR were capable of transforming biliverdin to bilirubin in vitro. The overexpression conditions were optimized to enhance BVR production by GS115-bvdR, and the optimal conditions for the biotransformation of biliverdin into bilirubin using resting GS115-bvdR cells were established (pH 5.0 buffer, at 30 °C for 24 h, with 200 mg/L biliverdin). Under these conditions, a bilirubin concentration of 153 mg/L was achieved, with a conversion of 76.2% from biliverdin. These findings provide valuable insights for future studies on the biosynthesis of bilirubin through metabolic engineering.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: